Céline Goeminne
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Céline Goeminne has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Fanny Vuotto
Service de Maladies Infectieuses, Centre Hospitalier Universitaire de Lille , F-59000 Lille
4 shared publications - Mouna Lazrek
CHU Lille, Service de Virologie, Lille, France
2 shared publications - Ady Assaf
Service des maladies infectieuses et tropicales CHU Lille Lille France
1 shared publication - André Vincentelli
Heart and Lung Institute, Cardiac Surgery Department, CHU Lille, F-59000
1 shared publication - Anne Gigandon
Service de Microbiologie Clinique, Hôpitaux Saint-Joseph et Marie-Lannelongue, Le Plessis-Robinson, France
1 shared publication Anne-Laure Piton
Department of Internal Medicine and Clinical immunology, Centre de Référence des Maladies Autoimmunes Systémiques Rares du Nord et Nord-Ouest de France (CeRAINO), CHU Lille, Lille, France
1 shared publication
Latest Publications
- Open Access
- 29 January 2026
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (4) , 859-869
Invasive mold infection in heart transplant recipients: A nationwide multicenter matched case–control study between 2008 and 2022 in France
- 29 January 2026
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (4) , 859-869
Open AccessInvasive mold infection in heart transplant recipients: A nationwide multicenter matched case–control study between 2008 and 2022 in France
- 29 August 2023
- Published by Wiley in Clinical Transplantation
- Vol. 37 (12) , e15109
Reliability of QuantiFERON®‐CMV in predicting CMV recurrence in heart transplant recipients: A single‐center retrospective study
Background: Recurrence after Cytomegalovirus (CMV) infection in heart transplant recipients is difficult to predict, in spite of its high incidence. Secondary prophylaxis could reduce this burden; however, its duration remains unestablished. We evaluated the QuantiFERON®‐CMV test to see if it could predict CMV recurrence and help optimize the duration of secondary prophylaxis.Methods: This observational retrospective single center study included all heart transplant recipients who developed CMV infection between 2019 and 2021, with the CD8+ T‐cell‐mediated CMV immunity QuantiFERON®‐CMV test assessed at the time of (val)ganciclovir curative treatment completion. The main outcomes were CMV recurrence and duration of secondary prophylaxis. Secondary outcomes included immunosuppressive regimen, rejection, lymphocyte count, CMV viral load, infection type, and duration as possible confounding factors for recurrence.Results: Among the 15 patients included, five (33%) experienced recurrence, of whom three (60%) had a positive QuantiFERON®‐CMV test. The duration of secondary prophylaxis was similar regardless of QF‐CMV positivity. No confounding factor was significantly associated with CMV recurrence; however, it occurred in only 1/7 (14%) of the patients receiving an everolimus‐containing immunosuppressive regimen.Conclusion: In the population of heart transplant recipients, most of whom received ATG‐based induction, the QuantiFERON®‐CMV assay may not accurately predict CMV recurrence and would have not helped refining the duration of secondary prophylaxis in our patients. Other cell‐mediated immunity tests and strategies in this specific population, including everolimus‐containing regimens, may help predict and manage CMV recurrence.
- 29 August 2023
- Published by Wiley in Clinical Transplantation
- Vol. 37 (12) , e15109
Reliability of QuantiFERON®‐CMV in predicting CMV recurrence in heart transplant recipients: A single‐center retrospective study
Background: Recurrence after Cytomegalovirus (CMV) infection in heart transplant recipients is difficult to predict, in spite of its high incidence. Secondary prophylaxis could reduce this burden; however, its duration remains unestablished. We evaluated the QuantiFERON®‐CMV test to see if it could predict CMV recurrence and help optimize the duration of secondary prophylaxis.Methods: This observational retrospective single center study included all heart transplant recipients who developed CMV infection between 2019 and 2021, with the CD8+ T‐cell‐mediated CMV immunity QuantiFERON®‐CMV test assessed at the time of (val)ganciclovir curative treatment completion. The main outcomes were CMV recurrence and duration of secondary prophylaxis. Secondary outcomes included immunosuppressive regimen, rejection, lymphocyte count, CMV viral load, infection type, and duration as possible confounding factors for recurrence.Results: Among the 15 patients included, five (33%) experienced recurrence, of whom three (60%) had a positive QuantiFERON®‐CMV test. The duration of secondary prophylaxis was similar regardless of QF‐CMV positivity. No confounding factor was significantly associated with CMV recurrence; however, it occurred in only 1/7 (14%) of the patients receiving an everolimus‐containing immunosuppressive regimen.Conclusion: In the population of heart transplant recipients, most of whom received ATG‐based induction, the QuantiFERON®‐CMV assay may not accurately predict CMV recurrence and would have not helped refining the duration of secondary prophylaxis in our patients. Other cell‐mediated immunity tests and strategies in this specific population, including everolimus‐containing regimens, may help predict and manage CMV recurrence.
- Open Access
- 12 May 2021
- Published by Radcliffe Medical Media Ltd in Cardiac Failure Review
- Vol. 7
Fatal Enterovirus-related Myocarditis in a Patient with Devic’s Syndrome Treated with Rituximab
Enteroviruses are a frequent source of infection and among the most common central nervous system viral pathogens. Enteroviruses – in particular, the Coxsackie B viruses – are a known cause of myocarditis. Rituximab is a genetically engineered chimeric anti-CD20 monoclonal antibody. Many reports in the literature suggest a higher risk of infection following repeated rituximab therapy, including viral infection. However, observations of enterovirus-related myocarditis in the context of rituximab treatment are scarce. The authors describe the case of a patient with neuromyelitis optica spectrum disorder who developed severe and fatal enterovirus-related myocarditis after rituximab therapy with a difficult differential diagnosis of autoimmune or giant-cell myocarditis. This case highlights the importance of complete diagnostic workup in difficult cases of myocarditis, including endomyocardial biopsies.
- 12 May 2021
- Published by Radcliffe Medical Media Ltd in Cardiac Failure Review
- Vol. 7
Open AccessFatal Enterovirus-related Myocarditis in a Patient with Devic’s Syndrome Treated with Rituximab
Enteroviruses are a frequent source of infection and among the most common central nervous system viral pathogens. Enteroviruses – in particular, the Coxsackie B viruses – are a known cause of myocarditis. Rituximab is a genetically engineered chimeric anti-CD20 monoclonal antibody. Many reports in the literature suggest a higher risk of infection following repeated rituximab therapy, including viral infection. However, observations of enterovirus-related myocarditis in the context of rituximab treatment are scarce. The authors describe the case of a patient with neuromyelitis optica spectrum disorder who developed severe and fatal enterovirus-related myocarditis after rituximab therapy with a difficult differential diagnosis of autoimmune or giant-cell myocarditis. This case highlights the importance of complete diagnostic workup in difficult cases of myocarditis, including endomyocardial biopsies.
- Open Access
- 1 September 2020
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 39 (9) , 983-985
Heart retransplantation following COVID-19 illness in a heart transplant recipient
- 1 September 2020
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 39 (9) , 983-985
Open AccessHeart retransplantation following COVID-19 illness in a heart transplant recipient